Program
vosoritide
Also written as “BMN 111”, “Vosoritide” and “Vosoritide Injection”.
Its studies are mostly in Achondroplasia · Noonan Syndrome · Dwarfism, led by BioMarin Pharmaceutical.
Furthest: phase 3, since May 23, 201714 company-led studies, 7 open or runningNext primary completion: Dec 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BioMarin Pharmaceutical | 147 open or running | phase 3since May 23, 2017 | Mar 14, 2012 | Dec 2027phase 2 · NCT04554940 |
Also a collaborator on its studies: icon-clinical-research.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Mar 14, 2012.
- Apr 18, 2013Phase 2 study in AchondroplasiaNCT02055157 · 35 enrolled · United States, Australia, France and more
- Feb 12, 2016Phase 2 study in AchondroplasiaNCT02724228 · 30 enrolled · United States, Australia, France and more
- May 23, 2017Phase 3 study in AchondroplasiaNCT03197766 · 121 enrolled · United States, Australia, Germany and more
- Dec 28, 2017Phase 3 study in AchondroplasiaNCT03424018 · 119 enrolled · United States, Australia, Germany and more
- Jun 14, 2018Phase 2 study in AchondroplasiaNCT03583697 · 75 enrolled · United States, Australia, Japan and more
- May 22, 2019Phase 2 study in AchondroplasiaNCT03989947 · 73 enrolled · United States, Australia, Japan and more
- Sep 14, 2020Phase 2 study in AchondroplasiaNCT04554940 · 20 enrolled · Australia, United Kingdom
- Mar 16, 2023Phase 1 study in AchondroplasiaNCT05813314 · 36 enrolled · United States
- Apr 19, 2024Phase 2 study in Idiopathic Short StatureNCT06382155 · 100 planned · United States, Australia, France and more
- Jun 7, 2024Phase 3 study in HypochondroplasiaNCT06455059 · 81 enrolled · United States, Australia, Canada and more
- Oct 30, 2024Phase 2 study in Noonan SyndromeNCT06668805 · 18 enrolled · United States, Australia, Canada and more
- Jun 27, 2025Phase 3 study in HypochondroplasiaNCT07073014 · 140 planned · United States, Australia, Canada and more
- Jul 29, 2025Phase 2 study in HypochondroplasiaNCT07126262 · 60 planned · United States, Australia, France and more
- Nov 13, 2026Phase 2 study terminatedStudy stoppedNCT06668805 · “BioMarin has decided to discontinue the study after assessing a number of factors, including study feasibility and the current treatment …”
Ahead
- Dec 2027Primary completion: phase 2 study in AchondroplasiaNCT04554940
- Dec 2027Primary completion: phase 2 study in AchondroplasiaNCT02724228
- Jun 30, 2028Primary completion: phase 2 study in HypochondroplasiaNCT07126262
- Jun 2031Primary completion: phase 3 study in AchondroplasiaNCT03424018
TargetBeta
NPR2 →read by rule
“Atrial natriuretic peptide receptor B binding agent”ChEMBL 37, by rule
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07126262Hypochondroplasia · United States, Australia, France and more | 2 | Recruiting | Jun 30, 2028 | 60 |
| NCT07073014Hypochondroplasia · United States, Australia, Canada and more | 3 | By invitation | Oct 2044 | 140 |
| NCT06668805Noonan Syndrome · United States, Australia, Canada and more | 2 | Terminated | Sep 16, 2026 | 18 |
| NCT06455059Hypochondroplasia · United States, Australia, Canada and more | 3 | Completed | Apr 23, 2026 | 81 |
| NCT06382155Idiopathic Short Stature · United States, Australia, France and more | 2 | Recruiting | Jun 2026 | 100 |
| NCT05813314Achondroplasia · United States | 1 | Terminated | Jun 14, 2023 | 36 |
| NCT04554940Achondroplasia · Australia, United Kingdom | 2 | Active, not recruiting | Dec 2027 | 20 |
| NCT03989947Achondroplasia · United States, Australia, Japan and more | 2 | Active, not recruiting | May 2038 | 73 |
| NCT03583697Achondroplasia · United States, Australia, Japan and more | 2 | Completed | Jan 26, 2022 | 75 |
| NCT03424018Achondroplasia · United States, Australia, Germany and more | 3 | Active, not recruiting | Jun 2031 | 119 |
| NCT03197766Achondroplasia · United States, Australia, Germany and more | 3 | Completed | Oct 30, 2019 | 121 |
| NCT02724228Achondroplasia · United States, Australia, France and more | 2 | Active, not recruiting | Dec 2027 | 30 |
| NCT02055157Achondroplasia · United States, Australia, France and more | 2 | Completed | Oct 2, 2017 | 35 |
| NCT01590446Achondroplasia · United States | 1 | Completed | Jun 2012 | 74 |
How it is read
Names in the registry
- “BMN 111”, 6 entries
- “Vosoritide”, 3 entries
- “Vosoritide Injection”, 2 entries
- “vosoritide”, 1 entry
- “Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.”, 1 entry
Conditions, from the studies’ own filings
- Achondroplasia, 9 studies
- Noonan Syndrome, 1 study
- Dwarfism, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.